To define the inclusion/exclusion status of patients with brain metastasis in phase-III clinical trials and the effect of systemic therapies in metastatic renal cell cancer patients with brain metastasis.
Methods
“kidney neoplasms”[MeSH Terms] OR (“kidney”[All Fields] AND “neoplasms”[All Fields]) OR “kidney neoplasms”[All Fields] OR (“kidney”[All Fields] AND “cancer”[All Fields]) OR “kidney cancer”[All Fields] AND “brain metastasis” were used for searching “PubMed” electronic database and “clinicaltrials.gov” website.
Results
Five of 19 landmark phase-III clinical trials included patients with stable or asymptomatic brain metastasis and there was no data about outcomes of brain metastasis. The effect of systemic therapy on prevention of brain metastasis in renal cell cancer was evaluated in four studies. Two studies showed that the incidence of brain metastasis decreased, while the other two studies showed no effect of antiangiogenic agents on the prevention of brain metastasis in patients with renal cell cancer. There were 10 trials regarding systemic therapy of renal cell cancer brain metastasis. The overall response rate improved through a combination of targeted therapies and local treatment. The results of the trials studying the effect of tyrosine kinase inhibitors without local treatment were controversial. None of the ongoing clinical trials included patients with active brain metastasis.
Conclusion
In metastatic renal cell cancer patients with brain metastasis, the overall response rate improved with the combination of targeted agents and local treatment. Further trials are needed to evaluate the effect of systemic treatment on the prevention or treatment of brain metastasis in patients with renal cell cancer.
SunMDe VelascoGBrastianosPK, et al.
The development of brain metastases in patients with renal cell carcinoma: epidemiologic trends, survival, and clinical risk factors using a population-based cohort. Eur Urol Focus2019;
5: 474–481.
5.
SchoutenLJRuttenJHuveneersHA, et al.
Incidence of brain metastases in a cohort of patients with carcinoma of the breast, colon, kidney, and lung and melanoma.Cancer2002;
94: 2698–2705.
6.
ShuchBLa RochelleJCKlatteT, et al.
Brain metastasis from renal cell carcinoma: presentation, recurrence, and survival.Cancer2008;
113: 1641–1648.
7.
GoreMEHariharanSPortaC, et al.
Sunitinib in metastatic renal cell carcinoma patients with brain metastases.Cancer2011;
117: 501–509.
8.
RamalingamSGeorgeDJHarrisonMR.How we treat brain metastases in metastatic renal cell carcinoma. Clin Adv Hematol Oncol2018;
16: 110–114. 2018/05/10.
9.
WowraBSiebelsMMuacevicA, et al.
Repeated gamma knife surgery for multiple brain metastases from renal cell carcinoma.J Neurosurg2002;
97: 785–793.
10.
WronskiMMaorMHDavisBJ, et al.
External radiation of brain metastases from renal carcinoma: a retrospective study of 119 patients from the M. D. Anderson Cancer Center. Int J Radiat Oncol Biol Phys1997;
37: 753–759. 1997/03/01.
11.
CardenCPLarkinJMRosenthalMA.What is the risk of intracranial bleeding during anti-VEGF therapy?Neuro Oncol2008;
10: 624–630.
12.
HudesGCarducciMTomczakP, et al.
Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma.N Engl J Med2007;
356: 2271–2281.
13.
MotzerRJHutsonTETomczakP, et al.
Sunitinib versus interferon alfa in metastatic renal-cell carcinoma.N Engl J Med2007;
356: 115–124.
14.
EscudierBEisenTStadlerWM, et al.
Sorafenib in advanced clear-cell renal-cell carcinoma.N Engl J Med2007;
356: 125–134.
15.
MotzerRJEscudierBOudardS, et al.
Phase 3 trial of everolimus for metastatic renal cell carcinoma: final results and analysis of prognostic factors.Cancer2010;
116: 4256–4265.
16.
SternbergCNHawkinsREWagstaffJ, et al.
A randomised, double-blind phase III study of pazopanib in patients with advanced and/or metastatic renal cell carcinoma: final overall survival results and safety update.Eur J Cancer2013;
49: 1287–1296.
17.
RiniBIHalabiSRosenbergJE, et al.
Phase III trial of bevacizumab plus interferon alfa versus interferon alfa monotherapy in patients with metastatic renal cell carcinoma: final results of CALGB 90206.J Clin Oncol2010;
28: 2137–2143.
18.
EscudierBBellmuntJNegrierS, et al.
Phase III trial of bevacizumab plus interferon alfa-2a in patients with metastatic renal cell carcinoma (AVOREN): final analysis of overall survival.J Clin Oncol2010;
28: 2144–2150.
19.
RiniBIEscudierBTomczakP, et al.
Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial. Lancet2011;
378: 1931–1939.
20.
MotzerRJNosovDEisenT, et al.
Tivozanib versus sorafenib as initial targeted therapy for patients with metastatic renal cell carcinoma: results from a phase III trial.J Clin Oncol2013;
31: 3791–3799.
21.
MotzerRJHutsonTECellaD, et al.
Pazopanib versus sunitinib in metastatic renal-cell carcinoma.N Engl J Med2013;
369: 722–731.
22.
HutsonTELesovoyVAl-ShukriS, et al.
Axitinib versus sorafenib as first-line therapy in patients with metastatic renal-cell carcinoma: a randomised open-label phase 3 trial. Lancet Oncol2013;
14: 1287–1294.
23.
MotzerRJPortaCVogelzangNJ, et al.
Dovitinib versus sorafenib for third-line targeted treatment of patients with metastatic renal cell carcinoma: an open-label, randomised phase 3 trial. Lancet Oncol2014;
15: 286–296.
24.
RiniBIBellmuntJClancyJ, et al.
Randomized phase III trial of temsirolimus and bevacizumab versus interferon alfa and bevacizumab in metastatic renal cell carcinoma: INTORACT trial. J Clin Oncol2014;
32: 752–759.
25.
HutsonTEEscudierBEstebanE, et al.
Randomized phase III trial of temsirolimus versus sorafenib as second-line therapy after sunitinib in patients with metastatic renal cell carcinoma.J Clin Oncol2014;
32: 760–767.
26.
ChoueiriTKEscudierBPowlesT, et al.
Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial. Lancet Oncol2016;
17: 917–927.
27.
MotzerRJEscudierBMcDermottDF, et al.
Nivolumab versus everolimus in advanced renal-cell carcinoma.N Engl J Med2015;
373: 1803–1813.
28.
EichelbergCVervenneWLDe SantisM, et al.
SWITCH: a randomised, sequential, open-label study to evaluate the efficacy and safety of sorafenib-sunitinib versus sunitinib-sorafenib in the treatment of metastatic renal cell cancer.Eur Urol2015;
68: 837–847.
29.
RiniBIStenzlAZdrojowyR, et al.
IMA901, a multipeptide cancer vaccine, plus sunitinib versus sunitinib alone, as first-line therapy for advanced or metastatic renal cell carcinoma (IMPRINT): a multicentre, open-label, randomised, controlled, phase 3 trial. Lancet Oncol2016;
17: 1599–1611.
30.
MotzerRJTannirNMMcDermottDF, et al.
Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma.N Engl J Med2018;
378: 1277–1290.
31.
VanhuyseMPenelNCatyA, et al.
Do anti-angiogenic therapies prevent brain metastases in advanced renal cell carcinoma?Bull Cancer2012;
99: 100–106.
32.
VermaJJonaschEAllenP, et al.
Impact of tyrosine kinase inhibitors on the incidence of brain metastasis in metastatic renal cell carcinoma.Cancer2011;
117: 4958–4965.
33.
MassardCZonierekJGross-GoupilM, et al.
Incidence of brain metastases in renal cell carcinoma treated with sorafenib.Ann Oncol2010;
21: 1027–1031.
34.
MotzerRJRavaudAPatardJJ, et al.
Adjuvant sunitinib for high-risk renal cell carcinoma after nephrectomy: subgroup analyses and updated overall survival results. Eur Urol2018;
73: 62–68.
35.
MatranaMRDuranCShettyA, et al.
Outcomes of patients with metastatic clear-cell renal cell carcinoma treated with pazopanib after disease progression with other targeted therapies.Eur J Cancer2013;
49: 3169–3175.
36.
HelgasonHHMalloHADroogendijkH, et al.
Brain metastases in patients with renal cell cancer receiving new targeted treatment.J Clin Oncol2008;
26: 152–154.
37.
StadlerWMFiglinRAMcDermottDF, et al.
Safety and efficacy results of the advanced renal cell carcinoma sorafenib expanded access program in North America.Cancer2010;
116: 1272–1280.
38.
BastosDAMolinaAMHatzoglouV, et al.
Safety and efficacy of targeted therapy for renal cell carcinoma with brain metastasis.Clin Genitourin Cancer2015;
13: 59–66.
39.
De GiorgiUCarteniGGiannarelliD, et al.
Safety and efficacy of nivolumab for metastatic renal cell carcinoma: real-world results from an expanded access programme.BJU Int2019;
123: 98–105.
40.
DudnikEYust-KatzSNechushtanH, et al.
Intracranial response to nivolumab in NSCLC patients with untreated or progressing CNS metastases.Lung Cancer2016;
98: 114–117.
41.
VickersMMAl-HarbiHChoueiriTK, et al.
Prognostic factors of survival for patients with metastatic renal cell carcinoma with brain metastases treated with targeted therapy: results from the international metastatic renal cell carcinoma database consortium.Clin Genitourin Cancer2013;
11: 311–315.
42.
StaehlerMHasekeNNuhnP, et al.
Simultaneous anti-angiogenic therapy and single-fraction radiosurgery in clinically relevant metastases from renal cell carcinoma.BJU Int2011;
108: 673–678.
43.
CochranDCChanMDAkliluM, et al.
The effect of targeted agents on outcomes in patients with brain metastases from renal cell carcinoma treated with Gamma Knife surgery.J Neurosurg2012;
116: 978–983.
44.
SperdutoPWChaoSTSneedPK, et al.
Diagnosis-specific prognostic factors, indexes, and treatment outcomes for patients with newly diagnosed brain metastases: a multi-institutional analysis of 4,259 patients.Int J Radiat Oncol Biol Phys2010;
77: 655–661.
